ASMBS 2026
Bariatric surgery outperforms GLP-1s on weight loss, disease remission
Clinical takeaway: Surgery remains the more effective option for patients who need the magnitude and durability of outcomes that medications cannot consistently match.
GLP-1 receptor agonists have rapidly become a default obesity treatment, yet no randomized trials have directly compared them with bariatric surgery. This systematic review and real-world analysis pooled comparative data from 30 clinical studies covering more than 430,000 patients, addressing a key evidence gap as both treatments compete for the same patients.
Surgery exceeded GLP-1 therapy on every outcome measured. At 12 months, surgical patients achieved more than 20% greater weight loss. Remission rates for obesity-related conditions were also markedly higher with surgery, with absolute differences of 42% for type 2 diabetes, 21% for high cholesterol, and 13% for hypertension.
GLP-1 benefits typically reverse when therapy is discontinued, which is common in real-world use because of cost, side effects, or access. Surgery effects, by contrast, persist for years without ongoing pharmacotherapy. The findings suggest GLP-1s have expanded the evidence-based treatment options for obesity rather than replace surgery, particularly for patients with severe obesity or significant metabolic comorbidities.
The review pooled studies that directly compared the two treatments. The researchers disclosed consulting relationships with several drug and device makers, including two GLP-1 manufacturers. The study has not yet undergone full peer review.
Less than 1% of patients eligible for bariatric surgery undergo it in any given year, despite consistent evidence of its effectiveness. The findings reinforce surgery's place in the treatment hierarchy at a moment when patient and clinician attention has shifted heavily toward medication.
"While GLP-1 medications are an important advance, they do not match the magnitude or durability of outcomes achieved with metabolic and bariatric surgery, which remains one of the most underutilized treatments in medicine," said John Morton, MD, MPH, FASMBS, professor of surgery and vice-chair of quality at Yale School of Medicine. "Once the medications are discontinued, whether due to side effects, cost or other factors, their benefits often diminish or disappear, whereas the benefits of surgery endure."
Source: Morton J. ASMBS 2026 Annual Scientific Meeting Abstract 4223. Systematic review of comparative clinical trials for metabolic and bariatric surgery and glucagon-like peptide receptor agonists